Results 11 to 20 of about 37,394 (238)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. [PDF]

Blood Cancer J, 2018
Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained ...
Gertz MA.
europepmc   +5 more sources

Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach. [PDF]

J Adv Pract Oncol, 2019
Systemic immunoglobulin light-chain (AL) amyloidosis is a rare disorder arising from a plasma cell clone that produces misfolded immunoglobulin light chains, which are deposited in various tissues and organs as amyloid fibrils.
Hwa YL, Fogaren T, Sams A, Faller DV, Stull DM, Thuenemann S, Mendelson L.   +6 more
europepmc   +5 more sources

Modeling immunoglobulin light chain amyloidosis in Caenorhabditis elegans [PDF]

Disease Models & Mechanisms
AbstractCardiomyopathy determines the prognosis of patients with immunoglobulin light chain (AL) amyloidosis, a rare systemic disease caused by the misfolding and deposition of monoclonal light chains (LCs). The reasons underlining their cardiac tropism remain unknown, and an animal model recapitulating the main pathological features of AL amyloidosis ...
Margherita Romeo, Maria Monica Barzago, Alessandro Corbelli, Silvia Maglioni, Natascia Ventura, Carmina Natale, Andrea Conz, Mario Salmona, Giovanni Palladini, Mario Nuvolone, Fabio Fiordaliso, Giampaolo Merlini, Luisa Diomede   +12 more
doaj   +3 more sources

Immunoglobulin light chain amyloidosis [PDF]

memo - Magazine of European Medical Oncology, 2021
Immunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed life-threatening systemic disease, primarily caused by insoluble depositions of misfolded monoclonal light chains.
H. Agis, M. Krauth
semanticscholar   +2 more sources

Hereditary systemic immunoglobulin light-chain amyloidosis [PDF]

Blood, 2015
Several members of a family died from renal failure as a result of systemic amyloidosis. Extensive studies to detect previously documented gene mutations associated with amyloidosis failed to identify a causative factor.
Benson, Merrill D., Kluve-Beckerman, Barbara, Liepnieks, Juris J.   +2 more
core   +4 more sources

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

Hemato, 2022
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less common ...
Shayna Sarosiek, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +3 more
doaj   +2 more sources

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.

JAMA Oncol
Importance Kidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is ...
Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA.   +30 more
europepmc   +2 more sources

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. [PDF]

Blood Cancer J, 2020
Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and assess new response/progression criteria. Studies included were lenalidomide-
Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, Lin Y, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A.   +25 more
europepmc   +2 more sources

An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis

Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis
Background Each monoclonal antibody light chain associated with AL amyloidosis has a unique sequence. Defining how these sequences lead to amyloid deposition could facilitate faster diagnosis and lead to new treatments.
Vaishali Sanchorawala
exaly   +3 more sources

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. [PDF]

Blood Cancer J, 2023
Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A.   +5 more
europepmc   +2 more sources